



BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Avantor announces pricing of IPO

17 May 2019 | News

Avantor's common stock and Mandatory Convertible Preferred Stock will each be listed on the New York Stock Exchange, and each are expected to begin trading on May 17, 2019.



Avantor, a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries has announced that it has priced the initial public offering of 207,000,000 shares of its common stock at a price to the public of \$14.00 per share and a concurrent public offering of 18,000,000 shares of its 6.250% Series A Mandatory Convertible Preferred Stock at a price to the public of \$50.00 per share. In connection with the offerings, Avantor has granted the underwriters a 30-day option to purchase up to an additional 31,050,000 shares of common stock and an additional 2,700,000 shares of the Mandatory Convertible Preferred Stock, as applicable, in each case, solely to cover over-allotments. The offerings are expected to close on May 21, 2019, subject to customary closing conditions.

Avantor intends to use a portion of the net proceeds received from the offerings to redeem all outstanding shares of its existing Series A Preferred Stock and use the remaining proceeds to repay a portion of its outstanding indebtedness under its senior secured term loan facilities. The completion of the offering of Mandatory Convertible Preferred Stock is contingent upon the completion of the offering of common stock.

Avantor's common stock and Mandatory Convertible Preferred Stock will each be listed on the New York Stock Exchange, and each are expected to begin trading on May 17, 2019. Avantor's common stock will trade under the ticker symbol "AVTR," while the Mandatory Convertible Preferred Stock will begin trading under the ticker symbol "AVTR PRA."

Goldman Sachs & Co. LLC and J.P. Morgan are serving as the joint book-running managers and as representatives of the underwriters for the offerings. BofA Merrill Lynch, Barclays, Jefferies, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Guggenheim Securities, Morgan Stanley, UBS Investment Bank, Citigroup, Cowen, Piper Jaffray and RBC Capital Markets are also acting as bookrunners for the offerings. Baird, William Blair, Janney Montgomery Scott, KeyBanc Capital Markets, PJT Partners LP, Raymond James, Stephens Inc., Stifel, SunTrust Robinson Humphrey, Wells Fargo Securities and Drexel Hamilton are acting as co-managers for the offerings.

Unless converted earlier, each share of the Mandatory Convertible Preferred Stock will automatically convert on May 15, 2022 (subject to postponement for certain market disruption events) into between 3.0395 and 3.5714 shares of Avantor's common stock, subject to certain customary anti-dilution adjustments.

Dividends on the Mandatory Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by Avantor's board of directors, at an annual rate of 6.250% on the liquidation preference of \$50.00 per share. If declared, these dividends will be paid in cash, or, subject to certain limitations, in shares of Avantor's common stock or in a combination of cash and shares of Avantor's common stock, at Avantor's election, on February 15, May 15, August 15 and November 15 of each year, commencing on August 15, 2019, and continuing to, and including, May 15, 2022.

A registration statement, including separate prospectuses, relating to these securities, was declared effective by the Securities and Exchange Commission on May 16, 2019.

Avantor is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. We operate in more than 30 countries and deliver an extensive portfolio of products and services. We set science in motion to create a better world.